Alien Registration- Grondin, Irene (Lewiston, Androscoggin County)

https://digitalmaine.com/alien_docs/30219/thumbnail.jp

STRUCTURE DE FINANCEMENT ET COMPORTEMENT DE STOCKAGE ET D’ACCUMULATION DES FIRMES

Une importante littérature empirique est dévolue à la question du lien entre les facteurs financiers et les performances économiques des firmes. Dérivées du rejet de l’hypothèse classique de non incidence de la structure financière sur la dépense ou inscrites plutôt dans une logique de repérage des canaux de transmission de la politique monétaire, ces études s’intéressent pour la plupart, à travers l’analyse du cash flow, au rôle de la position financière de la firme dans la dépense. Leurs résultats attestent tous de la validité statistique et quantitative des influences financières. Les interprétations diffèrent cependant et un grand débat demeure quant à l’imputation de ces empreintes. Peut-on en effet les attribuer à l’offre de financement ou sont-elles plutôt issues du comportement des firmes ? Dans cette étude, où nous nous intéressons à un échantillon d’entreprises industrielles françaises adhérentes à la Centrale des Bilans, nous proposons d’élargir la gamme des variables qui peuvent entrer dans la définition de la position financière et patrimoniale de la firme afin d’explorer la manière dont elles expliquent les comportements réels de celle-ci. Dans l’analyse des déterminants des composantes de la demande, nous tentons de tenir compte, en plus des variables réelles conformément aux modèles théoriques sous-jacents, de l’ensemble des ressources et réserves internes détenues par la firme. Nous considérons également la capacité de la firme à recourir aux financements offerts par les partenaires extérieurs et apprécions en cela les liens qu’elle entretient avec ses fournisseurs de capitaux à travers la considération des différentes formes de financement externe. En plus de l’investissement productif souvent analysé dans les travaux empiriques, nous proposons dans cette étude de tenir compte également de l’activité courante de gestion de la firme à travers l’analyse de son comportement de stockage. Les analyses sont effectuées en premier lieu sur les années 87 d’une part et 93 d’autre part, ce qui correspond à deux périodes de crise bien typées du point de vue du cycle économique et monétaire. Des analyses de données sont ensuite menées sur des années de reprise économique sur l’ensemble de la période 1986-1995 et nous permettent d’apprécier comparativement les premiers résultats.accumulation, stockage, investissement, flexibilité financière, autonomie, découvert, régime de financement

Design and construction of a Cherenkov imager for charge measurement of nuclear cosmic rays

A proximity focusing Cherenkov imager called CHERCAM, has been built for the charge measurement of nuclear cosmic rays with the CREAM instrument. It consists of a silica aerogel radiator plane across from a detector plane equipped with 1,600 1" diameter photomultipliers. The two planes are separated by a ring expansion gap. The Cherenkov light yield is proportional to the charge squared of the incident particle. The expected relative light collection accuracy is in the few percents range. It leads to an expected single element separation over the range of nuclear charge Z of main interest 1 < Z < 26. CHERCAM is designed to fly with the CREAM balloon experiment. The design of the instrument and the implemented technical solutions allowing its safe operation in high altitude conditions (radiations, low pressure, cold) are presented.Comment: 24 pages, 19 figure

Paraben exposure through drugs in the neonatal intensive care unit: a regional cohort study

Background and objectives: Environmental factors influence the development of very preterm infants (VPIs, born at less than 32 weeks of gestation). It is important to identify all potential sources of paraben exposure in these vulnerable infants. We aimed to quantify paraben exposure via drug administration in a cohort of VPI cared for in neonatal intensive care units (NICUs).Methods: A prospective, observational study was carried out over a five-year period in a regional setting (two NICUs using the same computerized order-entry system). The main outcome was exposure to paraben-containing drugs. The secondary outcomes were: time of the first exposure, daily intake, number of infants exceeding paraben acceptable daily intake (ADI: 0–10 mg/kg/d), duration of exposure, and cumulative dose.Results: The cohort consisted of 1,315 VPIs [BW 1129.9 (±360.4) g]. Among them, 85.5% were exposed to paraben-containing drugs. In 40.4% of infants, the first exposure occurred during the second week of life. Mean paraben intake and duration of exposure were, respectively, 2.2 (±1.4) mg/kg/d and 33.1 (±22.3) days. The cumulative paraben intake was 80.3 (±84.6) mg/kg. The ADI was exceeded in 3.5% of exposed infants. Lower GA was associated with higher intake and longer exposure (p &lt; 0.0001). The main molecules involved in paraben exposure were: sodium iron feredetate, paracetamol, furosemide, and sodium bicarbonate + sodium alginate.Conclusion: Commonly used drugs are potential source of parabens, and ADI can be easily exceeded in VPIs cared for in NICUs. Efforts are needed to identify paraben-free alternative formulations for these vulnerable infants

Expansion of Regulatory T Cells in Patients with Langerhans Cell Histiocytosis

Frederic Geissmann and colleagues find that Langerhans cell accumulation in Langerhans cell histiocytosis results from survival rather than uncontrolled proliferation, and is associated with the expansion of regulatory T cells

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase&nbsp;1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation&nbsp;disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age&nbsp; 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score&nbsp; 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc&nbsp;= 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N&nbsp;= 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in&nbsp;Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in&nbsp;Asia&nbsp;and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Research and Design of a Routing Protocol in Large-Scale Wireless Sensor Networks

无线传感器网络，作为全球未来十大技术之一，集成了传感器技术、嵌入式计算技术、分布式信息处理和自组织网技术，可实时感知、采集、处理、传输网络分布区域内的各种信息数据，在军事国防、生物医疗、环境监测、抢险救灾、防恐反恐、危险区域远程控制等领域具有十分广阔的应用前景。 本文研究分析了无线传感器网络的已有路由协议，并针对大规模的无线传感器网络设计了一种树状路由协议，它根据节点地址信息来形成路由，从而简化了复杂繁冗的路由表查找和维护，节省了不必要的开销，提高了路由效率，实现了快速有效的数据传输。 为支持此路由协议本文提出了一种自适应动态地址分配算——ADAR（AdaptiveDynamicAddre...As one of the ten high technologies in the future, wireless sensor network, which is the integration of micro-sensors, embedded computing, modern network and Ad Hoc technologies, can apperceive, collect, process and transmit various information data within the region. It can be used in military defense, biomedical, environmental monitoring, disaster relief, counter-terrorism, remote control of haz...学位：工学硕士院系专业：信息科学与技术学院通信工程系_通信与信息系统学号：2332007115216